RBR-2fqcbrx尚未招募2 期
A double-blind, randomized, placebo-controlled study to evaluate the efficacy of Eclipta prostrata (L.) L. in the treatment of atopic dermatitis in children above 2 years old
Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo - USP0 个研究点开始时间: 2022年12月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 2Y 至 18Y（—）
入选标准
- •Children and adolescents between 2 and 18 years old; clinical diagnosis of atopic dermatitis, according to the Hanifin and Rajka criteria
排除标准
- •Diagnosis or presence of acute or chronic cutaneous diseases, not suggestive of atopic dermatitis, that may interfere with the study results; use of corticosteroids, systemic immunosuppressants or immunobiologicals for at least 30 days before or during participation in the study; allergy or serious adverse events attributable to the administration of the investigational product; non-adherence to treatment (ie, not using the investigational product regularly, as prescribed) for at least one continuous month; failure to attend more than 50% of the evaluations (clinical and/or laboratory) that will be carried out during the study
研究者
相似试验
进行中（未招募）
1 期
A study of UCB0942 in adult patients with highly drug-resistant focal epilepsyEUCTR2014-003330-12-HUCB Biopharma SPR46
进行中（未招募）
1 期
A study of UCB0942 in adult patients with highly drug-resistant focal epilepsyhighly drug-resistant focal epilepsyMedDRA version: 21.1Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852EUCTR2014-003330-12-ITCB Biopharma SR55
招募中
1 期
Safety and efficacy of PC945 in combination with other antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (Opera-T Study)Refractory invasive pulmonary aspergillosis (IPA)MedDRA version: 20.0Level: LLTClassification code 10059259Term: Pulmonary aspergillosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-004554-32-ATPulmocide Ltd123
已完成
3 期
A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled seizuresNL-OMON47292GW Research Ltd25
已完成
不适用
A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending oral doses of ASP2905 in healthy young males, including an open-label two-period randomized crossover study to compare the pharmacokinetics under fasted and fed conditionsziekte van Alzheimer, schizofrenieAlzheimer's Disease and schizophrenyNL-OMON32022Astellas Pharma68